targeted protein degradation

WALTHAM, Massachusetts, and HANGZHOU, China, August 13, 2026 Photys Therapeutics, Inc. and Polymed Biopharmaceuticals, Inc. announced the initiation of...

BRISBANE, Calif., Aug. 4, 2026 Nurix Therapeutics, Inc. announced the enrollment of the first patient in the registrational Phase...

NEW HAVEN, Conn., July 27, 2026 Biohaven Ltd. and Yale University have secured a significant legal victory after a...

Brisbane, California, USA | July 21, 2026 Nurix Therapeutics announced the official closing of its previously announced global collaboration...

CAMBRIDGE, UK, June 8, 2026 Amphista Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the...

BRISBANE, Calif., May 14, 2026 Nurix Therapeutics presented new preclinical and Phase 1 translational data at the Society for...

BRISBANE, Calif., May 12, 2026 Nurix Therapeutics announced that updated clinical data for its investigational BTK degrader bexobrutideg (NX-5948)...

SOUTH SAN FRANCISCO, Calif., May 12, 2026 Rigel Pharmaceuticals has entered into an exclusive global licensing agreement with Arvinas...

CAMBRIDGE, UK, April 24, 2026 Amphista Therapeutics has unveiled new preclinical data demonstrating the therapeutic potential of its SMARCA2...

WATERTOWN, Massachusetts, April 9, 2026 Kymera Therapeutics has announced that Gilead Sciences has exercised its option to exclusively license...